Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258135 | 0.86 | CCNB2 (0.63) | CNR1DRD2HTR2AHTR2CCCNB2 | |
| SCHEMBL5258553 | 0.86 | CNR1 (0.47) | CNR1DRD2HTR2AHTR2CCCNB2 | |
| SCHEMBL5257842 | 0.83 | CCNB2 (0.46) | CNR1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5261524 | 0.82 | TUBB4A (0.47) | CNR1DRD2HTR2AHTR2CMAPT | |
| SCHEMBL5258148 | 0.77 | VDR (0.56) | KDM4EMAPT | |
| SCHEMBL5259798 | 0.74 | CNR1 (0.50) | CNR1HTR2AHTR2CCCNB2CDK1 | |
| SCHEMBL28974919 | 0.74 | CNR1 (0.54) | CNR1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5259127 | 0.74 | CNR1 (0.57) | CNR1DRD2HTR2AHTR2CCCNB2 | |
| SCHEMBL27574557 | 0.73 | CCNB2 (0.53) | CNR1DRD2HTR2AHTR2CCCNB2 | |
| SCHEMBL20105009 | 0.73 | CCNB2 (0.53) | CNR1DRD2HTR2AHTR2CCCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-7091220-B2 | Substituted indole Mannich bases | GRUENENTHAL GMBH (DE) | 2006-08-15 | — | — | US | claimed |
| CN-1219763-C | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2005-09-21 | — | — | CN | claimed |
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-7091220-B2 | Substituted indole Mannich bases | GRUENENTHAL GMBH (DE) | 2006-08-15 | — | — | US | disclosed |
| CN-1219763-C | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2005-09-21 | — | — | CN | disclosed |
| CN-1413192-A | Substituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-04-23 | — | — | CN | disclosed |
| US-20030060497-A1 | Subtituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-03-27 | — | — | US | disclosed |
| EP-1261585-A1 | SUBSTITUTED INDOLE MANNICH BASES | Grünenthal GmbH (DE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001047885-A1 | SUBSTITUTED INDOLE MANNICH BASES | Grünenthal GmbH (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060497-A1 | Subtituted indole mannich bases | TPH1, IDO1, TPH2 | CNR1 19/4885DRD2 310/4885HTR2A 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.